Results 11 to 20 of about 29,696 (222)

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line [PDF]

Current Issues in Molecular Biology, 2022
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection.
Yang De Marinis, Magnus Rasmussen, Markus Alden   +2 more
exaly   +6 more sources

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2 [PDF]

Vaccines, 2022
Emerging numbers of SARS-CoV-2 infections are currently combated with a third vaccination. Considering the different vaccination regimens used for the first two vaccine doses, we addressed whether the previous vaccination influences the immune response to the booster. Participants for this prospective study were recruited from among healthcare workers.
Rieke Reiter, Pia Von Blanckenburg, Reinier Mutters, Julia Thiemer, Reinhard Geßner, Ulf Seifart   +5 more
openaire   +5 more sources

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination [PDF]

Nature, 2021
Abstract Following severe adverse reactions in patients vaccinated with the AstraZeneca ChadOx1 (Chad) vaccine, European health authorities have recommended that patients under the age of 55 who received one dose of Chad vaccine receive a second dose of Pfizer BNT162b2 (BNT) vaccine as a booster.
Bruno Pozzetto, Vincent Legros, Sophia Djebali, Véronique Barateau, Nicolas Guibert, Marine Villard, Loïc Peyrot, Omran Allatif, Jean-Baptiste Fassier, Amélie Massardier-Pilonchéry, Karen Brengel-Pesce, Melyssa Yaugel-Novoa, Solène Denolly, Bertrand Boson, Thomas Bourlet, Antonin Bal, Martine Valette, Thibault Andrieu, Bruno Lina, Kahina Saker, Christelle Compagnon, Bouchra Mokdad, Constance d’Aubarede, Virginie Pitiot, Vanessa Escuret, Florence Morfin, Mary-Anne Trabaud, Margaux Prieux, Valérie Dubois, Laurence Josset, Soizic Daniel, François-Loïc Cosset, Stéphane Paul, Thierry Defrance, Jacqueline Marvel, Thierry Walzer, Sophie Trouillet-Assant   +36 more
openaire   +7 more sources

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose [PDF]

Wellcome Open Research, 2022
Abstract The two most commonly-used SARS-CoV-2 vaccines in the UK, BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca), employ different immunogenic mechanisms. Compared to BNT162b2, two-dose immunisation with ChAdOx1 induces substantially lower peak anti-spike antibody (anti-S) levels and is associated with a higher ...
Alexei Yavlinsky, Sarah Beale, Vincent Nguyen, Madhumita Shrotri, Thomas Byrne, Cyril Geismar, Ellen Fragaszy, Susan Hoskins, Wing Lam Erica Fong, Annalan M D Navaratnam, Isobel Braithwaite, Parth Patel, Jana Kovar, Andrew Hayward, Robert W Aldridge   +14 more
openaire   +6 more sources

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron [PDF]

iScience, 2022
Summary: Heterologous ChAdOx1-BNT162b2 vaccination induces a stronger immune response than BNT162b2-BNT162b2. Here, we investigated the molecular transcriptome, germline allelic variants of immunoglobulin loci, and anti-Omicron antibody levels in 46 ...
Hye Kyung Lee, Jinyoung Go, Heungsup Sung, Seong Who Kim, Mary Walter, Ludwig Knabl, Priscilla A. Furth, Lothar Hennighausen, Jin Won Huh   +8 more
doaj   +2 more sources

Acute myocarditis following administration of BNT162b2 vaccine [PDF]

IDCases, 2021
The wide use of vaccines was linked with rare but serious complications in adults, causing a global concern. Here, we describe a young male patient, who presented with acute myocarditis, three days after the second dose of BNT162b2 vaccine.
Mhd Baraa Habib, Tahseen Hamamyh, Ahmed Elyas, Mohammed Altermanini, Mawahib Elhassan   +4 more
openaire   +4 more sources

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination [PDF]

Vaccines, 2023
This study aimed to compare adverse reactions following BNT162b2 and influenza vaccinations in healthcare workers. This study included healthcare workers who received the BNT162b2 vaccine and/or inactivated influenza vaccine, quadrivalent (IIV4), on 18 ...
A-Sol Kim, Sung-Min Kim, Ji-Eun Song, Soyoon Hwang, Eunkyung Nam, Ki Tae Kwon   +5 more
doaj   +2 more sources

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [PDF]

New England Journal of Medicine, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently.In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned ...
Polack, Fernando P., Thomas, Stephen J., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Perez, John L., Pérez Marc, Gonzalo, Moreira, Edson D., Zerbini, Cristiano, Bailey, Ruth, Swanson, Kena A., Roychoudhury, Satrajit, Koury, Kenneth, Li, Ping, Kalina, Warren V., Cooper, David, Frenck Jr., Robert W., Hammitt, Laura L., Türeci, Özlem, Nell, Haylene, Schaefer, Axel, Ünal, Serhat, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.   +28 more
openaire   +4 more sources

Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections. [PDF]

J Med Virol
ABSTRACT This study aimed to assess the humoral immune response following administration of a BNT162b2 mRNA COVID‐19 booster dose and to evaluate its association with the development of SARS‐CoV‐2 infection after vaccination. Between July 2021 and February 2022, serum samples were collected from 313 individuals 28 days after receiving a COVID‐19 ...
Dinç HÖ, Uysal HK, Can G, Budak B, Daşdemir FO, Keskin E, Aydoğan O, Balkan İİ, Karaali R, Saribaş S, Ergin S, Saltoğlu N, Kocazeybek B.   +12 more
europepmc   +2 more sources

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results) [PDF]

Vaccines
Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability ...
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, Rohit Solan, Han Wu, Hua Ma, Xia Xu, Federico J. Mensa, Todd Belanger, David Cooper, Robin Mogg, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Pirada Suphaphiphat Allen, Kayvon Modjarrad, Alejandra Gurtman, Kelly Lindert   +17 more
doaj   +2 more sources